Xencor (XNCR) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $1.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +47.44%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.63 per share when it actually produced a loss of $0.66, delivering a surpr ...